Stereotactic body radiation therapy (SBRT) in the management of non-small-cell lung cancer: Clinical impact and patient perspectives

Abstract

Stereotactic body radiation therapy (SBRT) has emerged as a new technology in radiotherapy delivery, allowing for potentially curative treatment in many patients previously felt not to be candidates for radical surgical resection of stage I non-small-cell lung cancer (NSCLC). Several studies have demonstrated very high local control rates using SBRT, and more recent data have suggested overall survival may approach that of surgery in operable patients. However, SBRT is not without unique toxicities, and the balance of toxicity, and effect on patient-reported quality of life need to be considered with respect to oncologic outcomes. We therefore aim to review SBRT in the context of important patient-related factors, including quality of life in several domains (and in comparison to other therapies such as conventional radiation, surgery, or no treatment). We will also describe scenarios in which SBRT may be reasonably offered (i.e. elderly patients and those with severe COPD), and where it may need to be approached with some caution due to increased risks of toxicity (i.e. tumor location, patients with interstitial lung disease). In total, we hope to characterize the physical, emotional, and functional consequences of SBRT, in relation to other management strategies, in order to aid the clinician in deciding whether SBRT is the optimal treatment choice for each patient with early stage NSCLC.

Research on Current Curative Expenditure among Lung Cancer Patients Based on the “System of Health Accounts 2011”: Insights into Influencing Factors

“…In the context of precision medicine, breakthroughs continue to be achieved in treating lung cancer. Molecular targeted therapy, immunotherapy, and stereotactic body radiation therapy were verified as better treatment strategies in certain pathological types and some disease stages of lung cancer patients 49, 50. Therefore, in the future, we can refine the costs of different treatment methods and the types of patients, to provide more specific guidance for practice, which is also the future development trend.…”

Patterns of Pretreatment Diagnostic Assessment in Patients Treated with Stereotactic Body Radiation Therapy (SBRT) for Non-Small Cell Lung Cancer (NSCLC): Special Characteristics in the COVID Pandemic and Influence on Outcomes

“…During the pandemic, the contact reduction and the allocation of intensive care unit resources are of major importance [ 23 ]. Here, SBRT has advantages when compared to surgery [ 24 ]. Additionally, SBRT is favorable during the pandemic because it is applied in a few fractions and can be delivered as a convenient outpatient procedure [ 25 ].…”

Postoperative EGFR-TKI treatment on residual multiple ground-glass nodules after resection for lung adenocarcinoma:a case report and literature review

“…Wu et al [11] reports that GGNs may not be sensitive to anti-PD-1/PD-L1-based monotherapy or combinatorial therapy. SBRT can be considered to achieve local control [9,10].According to the National Comprehensive Cancer Network guideline for Non-Small Cell Lung Cancer (NSCLC) in 2021 [24], Osimertinib is recommended to be used as adjuvant treatment for EGFR-mutated early-stage NSCLC. However, it is unclear whether Osimertinib show e cacy on residual mGGNs after resection for dominant lesion harboring EGFR mutation.…”

“…Surgical treatment is usually the rst choice, but many GGNs patients are not eligible for complete surgical resection. In previous clinical innovation studies, chemotherapy [5,6], radiotherapy [7,8],stereotactic body radiation therapy (SBRT) [9,10], immunotherapy [11] and targeted therapy [12][13][14][15] have been reported, but no consensus results have been obtained. So, it's valuable to try more to explore effective treatment for GGNs.…”